Share This Article:

Cardiomyopathy protection in Chagas Disease

Abstract Full-Text HTML Download Download as PDF (Size:66KB) PP. 442-447
DOI: 10.4236/wjcd.2013.37069    4,430 Downloads   5,829 Views   Citations

ABSTRACT

There is some published evidence suggesting micro vascular endothelial dysfunction and dysautonomia involvement in Chagas disease in association with cardiomyocyte changes favoring disease progression. The combined treatment between angiotensin converting enzyme (ACE) inhibitor drugs; Simvastatin, muscarinic antibody immunoadsorbent together with fungicidal drugs would open therapeutic possibilities in this disease.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Mitelman, J. and Gimenez, L. (2013) Cardiomyopathy protection in Chagas Disease. World Journal of Cardiovascular Diseases, 3, 442-447. doi: 10.4236/wjcd.2013.37069.

References

[1] Schofield, C.J. (1989) American trypanosomiasis. In Geographical distribution of arthropod-borne diseases and their principal vectors. World Health Organization manual, WHO/VBC/89.967, 81-92.
[2] Report if a WHO (World Health Organization) informal consultation (jointly organized by WHO headquarters and the WHO regional office for Europe) (2009) Control and prevention of Chagas disease in Europe. Geneva, 1-74.
[3] Kirchhoff, L. (1993) American trypanosomiasis (Chagas’ disease): A tropical disease now in the United States. New England Journal of Medicine, 329, 639-644.
http://dx.doi.org/10.1056/NEJM199308263290909
[4] Pung, O.J., Banks, C.W., Jones, D.N. and Krissinger, M.W. (1995) Trypanosoma cruzi in wild raccoons, and triatomine bugs in southeast Georgia, USA. Journal of Parasitology, 81, 324-326.
http://dx.doi.org/10.2307/3283947
[5] Schofield, C.J. and Galvao, C. (2009) Classification, evolution and species groups within the Triatominae. Acta Tropica, 110, 88-100.
http://dx.doi.org/10.1016/j.actatropica.2009.01.010
[6] Morris, S., Tanowitz, H. and Murray, W. (1990) Pathophyphysiological Insights into the cardiomyopathy of Chagas’ disease. Circulation, 82, 1900-1908.
http://dx.doi.org/10.1161/01.CIR.82.6.1900
[7] Rosemberg, I. and Pereira, M. (1987) Smilitary of cruzan an inhibitor of Trypanosoma cruzi neuraminidase, to high-density lipoprotein. Science, 84, 10-12.
[8] Tarleton, R. (2001) Parasite persistence in the etiology of Chagas disease. International Journal for Parasitology, 31, 549-553.
http://dx.doi.org/10.1016/S0020-7519(01)00158-8
[9] Libby, P., Alroy, J. and Pereyra, M.E. (1986) A neuralminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells. Journal of Clinical Investigation, 77, 127-135.
http://dx.doi.org/10.1172/JCI112266
[10] Rossi, M.A. and Mengel, J.O. (1992) The pathogenesis of chronic Chagas myocarditis: The role of autoimmune and microvascular factors. Revista do Instituto de Medicina Tropical de Sao Paulo, 34, 539-599.
[11] Mordini, O., et al. (2010) Council of heart disease and Chagas disease. Time to update the clinical classification of the Chagas disease. Four seasons hotel Buenos aires 20/3/10, Pág, WEB, SIAC.
[12] Mitelman, J., et al. (2011) Consensus of Chagas Mazza Disease. Revista Argentina de Cardiología, 79, 544-564.
[13] Marin-Neto, J.A. (1998) Cardiac dysautonomy and pathogenesis of Chagas’ heart disease. International Journal of Cardiology, 66, 129-131.
[14] Redruello, M., Masoli, O., Perez Balino, N. and team (2003) Endothelial dysfunction in Chronic Chagas disease. Assesment with 99 mTc sestamibi Spect cold pressor test and intracoronary aceltylcholine. Journal of Nuclear Cardiology, 10, 9-26.
[15] Celermajer, D.S., Sorensen, K.E., Bull, C. and team. (1994) Endothelium dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. Journal of the American College of Cardiology, 24, 1468-1474.
http://dx.doi.org/10.1016/0735-1097(94)90141-4
[16] Celermajer, D.S., Sorensen, K.E., Geogakopoulos, D. and team (1993) Cigarette smoking is associated with doserelated and potentially reversible impairment of endothelium-dependent dilation. Circulation, 88, 2149-2155.
http://dx.doi.org/10.1161/01.CIR.88.5.2149
[17] Van Mourik, J.A., Boertjes, R., Huisveld, I.A. and team (1999) Von Willebrand, factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood, 94, 179-185.
[18] Iosa, D., Dequatro, V., De-Ping-Lee, D. and team (1990) Pathogenesis of cardiac neuropathy in Chagas disease and the role of autonomic nervous system. Journal of the Autonomic Nervous System, 30, 583-588.
http://dx.doi.org/10.1016/0165-1838(90)90107-T
[19] Goin, J.C., Perez Leiros, C., Borda, E. and Sterin-Borda, L. (1997) Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: Functional and pathological implications. The FASEB Journal, 11, 77-83.
[20] Sterin Borda, L. and Borda, E. (2000) Role of neurotransmitter autoantibodies in the pathogenesis of chagasic peripheral dysautonomia. Annals of the New York Academy of Sciences, 917, 273-280.
http://dx.doi.org/10.1111/j.1749-6632.2000.tb05393.x
[21] Matsumato, S., Labowsky, V., et al. (2006) Retinal dysfunction in patients with chronic Chagas disease is associated to anti-trypanosoma cruzi antibodies that crossreact with rhodopsim. The Faseb Journal, 20, 550-552.
[22] Salles, G., Xavier, S., Sousa, A., Hasslocher-Moreno, A. and Cardoso, C. (2003) Prognostic value of QT interval parameters for mortality risk stratification in Chagas’ disease: Results of a long-term follow-up study. Journal of the American Heart Association, 108, 305-312.
[23] Mitelman, J., Gimenez, L., Diaz, A., et al. (2001) Association between endothelial dysfunction assessed by ischemic test with brachial echo-Doppler and Von Willebrand factor in Chagas disease. Revista Argentina de Cardiología, 69, 275-278.
[24] Gimenez, L., Mitelman, J. and Gonzalez, C. (2003) Antiautonomic receptor antibodies, heart rate variability and arrhythmias in patients with Chagas disease. Revista Argentina de Cardiología, 71, 109-113.
[25] Mitelman, J., Gimenez, L., et al. (2000) Non invasive diagnostic methods for detection of functional anomalies in chronic Chagas disease. Revista Argentina de Cardiología, 68, 797-802.
[26] Mitelman, J., Gimenez, L. and Gonzalez, C. (2013) Valorar la asociación de pruebas diagnósticas incruentas para la detección de alteraciones funcionales miocárdicas autonómicas y endoteliales en la enfermedad de chagas. Revista Guatemalteca de Cardiología, 23, 16-20.
[27] Breithardt, G. and Cain, M. (1991) Flowers standards for analysis of ventricular late potential using high-resolution or signal averaged electrocardiography: A statement by a task force committee of the European Society of Cardiology, the American Heart Association and the American College of Cardiology. Journal of American College of Cardiology, 17, 999-1006.
http://dx.doi.org/10.1016/0735-1097(91)90822-Q
[28] Marek, M. (1996) Heart rate variability. Standards of measurement, physiological interpretation and clinical use task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation, 93, 1043-1065.
[29] Malik, M. and Camm, A.J. (1997) Mystery of QTc interval dispersion. American Journal of Cardiology, 49, 785-787.
[30] Mitelman, J., Gimenez, L., Ruggiero, M., et al. (2008) Cardiac rehabilitation in chagasic patients with heart failure. Revista Costarricense de Cardiología, 10.
[31] Mitelman, J., Giménez, L., Palacios, K., Tomasella, M., Acuna, L. and Avayú, D. (2011) New paradigms in Chagas Mazza disease.
www.intramed.net/contenidover.aspncontenidoID=71783

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.